HardCardiologyHeart failure with reduced ejection fractionau-amcau-racp
A 52-year-old man with HF with reduced ejection fraction (LVEF 30%) is on optimal doses of an ACE inhibitor, beta blocker and mineralocorticoid receptor antagonist. He remains NYHA class II with no recent decompensation. According to contemporary heart failure guidance, which additional therapy has proven morbidity and mortality benefit and should be considered?